Concepedia

Luis Llamas

LL

Statistics

Publications

11

Citations

505

H-Index

11

Active since

1983

Affiliations

Novartis (China)(Current)

Novartis (Switzerland)

Novartis (United States)

Athersys (United States)

Novartis Institutes for BioMedical Research

Luis Llamas is an author at Novartis (China) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

1983–2023

11

Publications

11

1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity

Karen Miller‐Moslin, Stefan Peukert, Rishi K. Jain et al. · Journal of Medicinal Chemistry · 2009 · 106 citations · Full text

, , +14

Discovery of a ZIP7 inhibitor from a Notch pathway screen

Erin Nolin, Sara Gans, Luis Llamas et al. · Nature Chemical Biology · 2018 · 71 citations · Full text

, , +13

Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39

Frédéric Bassilana, Adam Carlson, Jennifer DaSilva et al. · Nature Chemical Biology · 2014 · 66 citations

, , +16

Bile acid analogues are activators of pyrin inflammasome

Irina Alimov, Suchithra Menon, Nadire R. Cochran et al. · Journal of Biological Chemistry · 2019 · 63 citations · Full text

, , +17

Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

Stefan Peukert, Richard L. Hughes, Jill Nunez et al. · ACS Medicinal Chemistry Letters · 2014 · 54 citations · Full text

, , +16

1–5 of 11